Identification of hepatoma-derived growth factor as a potential prognostic and diagnostic marker for extrahepatic cholangiocarcinoma

World Journal of Surgery

Volumn 37, Issue 10, 2013, Pages 2419-2427

  Han, Yuxia ^a,b   Zhang, Wenxia ^a,b   Liu, Yanfeng ^b  

^a Binzhou Vocational College   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; HEPATOMA-DERIVED GROWTH FACTOR; SIGNAL PEPTIDE; TUMOR MARKER; HEPATOMA DERIVED GROWTH FACTOR;

ADULT; AGED; BILE DUCT NEOPLASMS; BLOOD; CASE CONTROL STUDY; CHOLANGIOCARCINOMA; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATIC DUCT; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR;

ADULT; AGED; ANTIGENS, CD34; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CASE-CONTROL STUDIES; CHOLANGIOCARCINOMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883554884     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-013-2132-4     Document Type: Article

References (32)

1. Khan SA, Thomas HC, Davidson BR et al (2005) Cholangiocarcinoma. Lancet 366:1303-1314
2. Patel T (2006) Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol 3:33-42
3. Jarnagin WR, Shoup M (2004) Surgical management of cholangiocarcinoma. Semin Liver Dis 24:189-199
4. Nakamura H, Kambe H, Egawa T et al (1989) Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 183:273-284
5. Nakamura H, Izumoto Y, Kambe H et al (1994) Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 269:25143-25149
6. Everett AD, Lobe DR, Matsumura ME et al (2000) Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 105:567-575
7. Kishima Y, Yamamoto H, Izumoto Y et al (2002) Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 277:10315-10322
8. Okuda Y, Nakamura H, Yoshida K et al (2003) Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci 94:1034-1041
9. Yoshida K, Nakamura H, Okuda Y et al (2003) Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J Gastroenterol Hepatol 18:1293-1301
10. Tsang TY, Tang WY, Tsang WP et al (2009) Mechanistic study on growth suppression and apoptosis induction by targeting hepatoma-derived growth factor in human hepatocellular carcinoma HepG2 cells. Cell Physiol Biochem 24:253-262
11. Meng J, Xie W, Cao L et al (2010) shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer. Acta Biochim Biophys Sin (Shanghai) 42:52-57
12. Hu TH, Huang CC, Liu LF et al (2003) Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 98:1444-1456
13. Ren H, Tang X, Lee JJ et al (2004) Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol 22:3230-3237
14. Uyama H, Tomita Y, Nakamura H et al (2006) Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 12:6043-6048
15. Yamamoto S, Tomita Y, Hoshida Y et al (2006) Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res 12:117-122
16. Yoshida K, Tomita Y, Okuda Y et al (2006) Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 13:159-167
17. Yamamoto S, Tomita Y, Hoshida Y et al (2007) Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol 14:2141-2149
18. Hu TH, Lin JW, Chen HH et al (2009) The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum 52:319-326
19. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
20. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027
21. Mobius C, Demuth C, Aigner T et al (2007) Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma. Eur J Surg Oncol 33:1025-1029
22. Zhang J, Ren H, Yuan P et al (2006) Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res 66:18-23
23. Mao J, Xu Z, Fang Y et al (2008) Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci 99:2120-2127
24. Lee KH, Choi EY, Kim MK et al (2010) Hepatoma-derived growth factor regulates the bad-mediated apoptotic pathway and induction of vascular endothelial growth factor in stomach cancer cells. Oncol Res 19:67-76
25. Ooi BN, Mukhopadhyay A, Masilamani J et al (2010) Hepatoma-derived growth factor and its role in keloid pathogenesis. J Cell Mol Med 14:1328-1337
26. Liu YF, Zhao R, Guo S et al (2011) Expression and clinical significance of hepatoma-derived growth factor as a prognostic factor in human hilar cholangiocarcinoma. Ann Surg Oncol 18:872-879
27. Zhang A, Long W, Guo Z et al (2010) Development and clinical evaluation of a multi-purpose mAb and a sandwich ELISA test for hepatoma-derived growth factor in lung cancer patients. J Immunol Methods 355:61-67
28. Weidner N, Semple JP, Welch WR et al (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324:1-8
29. Ren H, Chu Z, Mao L (2009) Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther 8:1106-1112
30. Yu Y, Shen H, Yu H et al (2011) Systematic proteomic analysis of human hepotacellular carcinoma cells reveals molecular pathways and networks involved in metastasis. Mol Biosyst 7:1908-1916
31. Patel AH, Harnois DM, Klee GG et al (2000) The utility of CA 19-9 in the diagnosis of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95:204-207
32. Akdogan M, Sasmaz N, Kayhan B et al (2001) Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori 87:337-339